Medical News

RSS

Antibacterial ingredient in honey identified

Sweet news for those looking for new antibiotics: A new research published in the July 2010 print edition of the FASEB Journal explains for the first time how honey kills bacteria. Specifically, the research shows that bees make a protein that they add to the honey, called defensin-1, which could one day be used to treat burns and skin infections and to develop new drugs that could combat antibiotic-resistant infections.

30 Jun 2010

DataCare completes Type II SAS 70 audit of Ahshay electronic workplace application

DataCare Corporation, the leader in web-based workers' compensation software, today announced it has successfully completed a Type II SAS 70 audit of Ahshay -- the company's electronic workplace application. The resulting Independent Service Auditor's Report certified that DataCare follows required procedures, has solid security controls, and protects clients' data in accordance with best practices.

30 Jun 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

GE Capital supports Guardian Healthcare with $90 million in senior secured credit facilities

GE Capital, Healthcare Financial Services provided and serves as administrative agent for $90 million in senior secured credit facilities to Guardian Healthcare, a leading Medicare-certified provider of professional home healthcare services. The credit facilities will be used for a significant acquisition and to refinance existing indebtedness. The remaining funds will be used for additional growth capital and general corporate purposes. GE Capital Markets served as the lead arranger for the credit facilities.

30 Jun 2010

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

TAP announces sale of first advanced micro bioreactor system

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, today announced it has sold its first advanced micro bioreactor system (ambr™) system to a global antibody therapeutics company, where ambr is being used to help predict how antibody expressing cell lines will behave in large scale bioreactors.

30 Jun 2010

Proton Therapy USA, CareCapital form Proton Therapy Global Management

Proton Therapy USA and CareCapital plc announced today the formation of Proton Therapy Global Management (PTGM). The Company will design, develop and manage a global network of proton therapy centers, providing access to this specialized and highly effective treatment to the world's growing population of cancer patients. Proton therapy is a precise form of radiation treatment that has been very successful in treating a wide range of localized tumors, while leaving healthy tissue mostly intact.

30 Jun 2010

SeqWright, RainDance Technologies partner to offer RainStorm microdroplet-based PCR technology

SeqWright Inc., a world-wide leader in custom genomic and molecular biology services, announced today the expansion of its service portfolio by partnering with RainDance Technologies to offer the company's innovative RainStorm™ microdroplet-based PCR technology. SeqWright recognizes the growing demand from life science researchers for more efficient and cost-effective processes that allow for automated workflows providing greater confidence in results to meet the needs of large-scale resequencing studies.

30 Jun 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

Fresenius Medical Care to acquire KNC and expand dialysis services business in Russian Federation

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, is expanding its dialysis services business in the Russian Federation. The company announced today that it has signed an agreement to acquire KNC (KRAEVOY NEFROLOGICHESKIY CENTR), a private operator of dialysis clinics in Russia's Krasnodar region. The acquired operations will add approximately $25 million in annual revenue and are expected to be accretive to earnings in the first year after closing of the transaction.

30 Jun 2010

AMI study finds India's healthcare sector set to spend over $250M on IT in 2010

Seemingly untouched by the worldwide economic downturn, India's healthcare sector is set to spend over US$250 million on IT in 2010. Healthcare in India comprises more than 5% of the nation's GDP and displays a healthy growth rate over the next four to five years. This comes from a study by New York-based Access Markets International (AMI) Partners, Inc., a leading consulting firm specializing in IT and telecom sectors.

30 Jun 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

GE Capital to provide Swift Group £30 million of dealer stocking funds

GE Capital announced that it agreed to provide Swift Group Ltd, the UK's leading manufacturer of caravans, motorhomes and holiday homes, with a distribution finance facility that will provide the company with an estimated £30 million of dealer stocking funds in 2010.

30 Jun 2010

First Edition: June 30, 2010

Today's headlines highlight the results of a new tracking poll that indicate that the health reform law has gained popularity among Americans while implementation advances for overhaul initiatives such as high-risk pools and the early retiree reinsurance program.

30 Jun 2010

Epigentek develops new approach for identification of "sixth DNA base" 5-hmC

Research experts in the epigenetic field from Epigentek have developed a new, breakthrough approach for the identification of the "sixth DNA base," 5-hydroxymethylcytosine (5-hmC). This technology is based on a high throughput, strip-well format and is also incorporated into the first commercially available product, the MethylFlash(TM) Hydroxymethylated DNA Quantification Kit, for rapidly quantifying hydroxymethylated DNA.

30 Jun 2010

AdVnt launches 15 Minute Black Mold Detection Test

AdVnt Biotechnologies, the company known for producing BioWarfare Agent Detection Devices for HAZMAT First Response Teams around the globe to help them rapidly detect such biological agents as Anthrax, Ricin and Botulinum, has just released its newest product for In-Home and Professional use. Building on the expertise gained in the international arena of BioWarfare Agent Detection, AdVnt is now applying its R&D expertise to help defend against another type of bio threat that could be growing in the walls and under the floorboards in your own home.

30 Jun 2010

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Blue Shield of California is now offering the Healthways SilverSneakers® Fitness Program to subscribers of Blue Shield Medicare Supplement Plans throughout California. SilverSneakers, the nation's leading social support and exercise program designed to keep seniors healthy, has been a popular benefit with California Medicare HMOs, but Blue Shield is one of the few health plans in the state to offer the benefit as part of its Medicare Supplement plans as well.

30 Jun 2010

Medical News

Antibacterial ingredient in honey identified

DataCare completes Type II SAS 70 audit of Ahshay electronic workplace application

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

GE Capital supports Guardian Healthcare with $90 million in senior secured credit facilities

Vicept completes $16 million Series A financing

Calistoga Pharmaceuticals closes $40 million Series C financing

TAP announces sale of first advanced micro bioreactor system

Proton Therapy USA, CareCapital form Proton Therapy Global Management

SeqWright, RainDance Technologies partner to offer RainStorm microdroplet-based PCR technology

Investment report on BioCryst Pharmaceuticals

Fresenius Medical Care to acquire KNC and expand dialysis services business in Russian Federation

AMI study finds India's healthcare sector set to spend over $250M on IT in 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

GE Capital to provide Swift Group £30 million of dealer stocking funds

First Edition: June 30, 2010

Epigentek develops new approach for identification of "sixth DNA base" 5-hmC

AdVnt launches 15 Minute Black Mold Detection Test

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News